{{howto|time=2014-03-16T05:06:27+00:00}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 452028402
| IUPAC_name = 8-[(3''R'')-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1''H''-purine-2,6-dione
| image = Linagliptin.png

<!--Clinical data-->
| tradename = Tradjenta, Trajenta
| Drugs.com = {{drugs.com|CDI|linagliptin}}
| MedlinePlus = a611036
| licence_EU        = Trajenta
| licence_US = Linagliptin
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = B
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  30% oral
| protein_bound =  75% to 99% in plasma 
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| IUPHAR_ligand = 6318
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 668270-12-0
| ATC_prefix = A10
| ATC_suffix = BH05
| ATC_supplemental =  
| PubChem = 10096344
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 237500
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 3X29ZEJ4R2
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D09566
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID      = 8271879


<!--Chemical data-->
| chemical_formula =  
| C=25 | H=28 | N=8 | O=2 
| molecular_weight = 472.54 g/mol
| smiles            = CC#CCN1C2=C(N=C1N3CCC[C@H](C3)N)N(C(=O)N(C2=O)CC4=NC5=CC=CC=C5C(=N4)C)C
| InChI             = 1/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
| InChIKey          = LTXREWYXXSTFRX-QGZVFWFLBX
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI          = 1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35)33(23(21)34)15-20-27-16(2)18-10-6-7-11-19(18)28-20/h6-7,10-11,17H,8-9,12-15,26H2,1-3H3/t17-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey       = LTXREWYXXSTFRX-QGZVFWFLSA-N
}}

'''利拉利汀'''（'''Linagliptin'''），或称利格列汀，屬於新一代DPP-4抑制劑（dipeptidyl peptidase (DPP)-4 inhibitors）的[[糖尿病|糖尿病]]藥物，於2011年5月獲[[美國食品及藥物管理局|美國食品及藥物管理局]](FDA)核准，在配合飲食及運動下，用於治療成年人[[二型糖尿病|二型糖尿病]]<ref>FDA approves new treatment for Type 2 diabetes. 3 May 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.htm {{Wayback|url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.htm |date=20131103093137 }}. Accessed 25 February 2012.</ref>。「利拉利汀」是目前唯一一種非主經腎臟排出體外的DPP-4抑制劑口服抗糖尿病藥。多項研究發現，只有5% 的「利拉利汀」藥物由腎臟排出<ref>Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, Withopf B, Wagner K. The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 2010 Apr;38(4):667-678.</ref>，其餘大部分未經代謝的藥物會由膽汁及腸道排泄出來，並不如其他同類口服糖尿病藥物(如﹕[[Sitagliptin|Sitagliptin]]「[[西他列汀|西他列汀]]」、[[Vildagliptin|Vildagliptin]]「[[維格列汀|維格列汀]]」及[[Saxagliptin|Saxagliptin]]「[[沙格列汀|沙格列汀]]」) 有近7成至9成經腎臟排出 <ref>Carolyn F Deacon, Jens J Holst. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: comparison, efficacy and safety. Informa Healthcare Expert Opinion Reviews. October 2013, Vol. 14, No. 15 , Pages 2047-2058.</ref><ref>Sitagliptin summary of product characteristics. Available at www.medicines.org.uk/emc/medicine/19609. </ref><ref>Vildaliptin summary of product characteristics. Available at www.medicines.org.uk/emc/medicine/20734.</ref><ref>Saxagliptin summary of product characteristics. Available at www.medicines.org.uk/EMC/medicine/22315.</ref> 。

「利拉利汀」由德國藥廠研發，與美國藥廠共同推廣，商品名為Trajenta，中文商品則名為 「糖漸平」(台灣) 、「糖安達」（香港）或「歐唐寧」（中國大陸）。

== 作用機制==
[[二肽基肽酶-4|二肽基肽酶-4]]（DPP-4）是人體酵素的一種，能迅速分解兩種腸促胰島素，包括胰升糖素樣肽（GLP-1）及腸抑胃肽（GIP）。GLP-1和GIP的功能，是刺激胰臟beta細胞製造及分泌胰島素，特別是在進食後血糖水平升高時。GLP-1還有另一項功能，就是抑制胰臟alpha細胞分泌胰升糖素，從而減少肝糖的製造。因此，作為DPP-4抑制劑，「利拉利汀」(linagliptin) 能夠在血糖濃度高時黏附於DPP-4上，阻止其分解腸促胰島素<ref>Thomas L, Tadayyon M, Mark M. Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 135 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazol in-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models. J Pharmacol Exp Ther 2009;328(2):556-563. </ref>，延長GLP-1和GIP的壽命，從而促進胰島素分泌，降低胰升糖素水平，改善血糖控制。

DPP-4抑制劑標誌着二型糖尿病治療的一個創新方向，作用機制獨特，與其他類型的二型糖尿病藥物有別。 <br />

== 臨床研究==
[[File:Linagliptin_Synthesis.svg|缩略图]]
「利拉利汀」(linagliptin)已完成第三期臨床試驗計劃，以証實單獨治療及合併其他常用抗糖尿病藥（例如[[甲福明|甲福明]]、[[磺胺脲類|磺胺脲類]]或[[格列酮類|格列酮類]]）的療效、安全性與耐受性。整個計劃的試驗中心分佈全球約40個國家，共納入超過5,000名二型糖尿病病人，當中有過千名病人患有不同程度的腎功能受損，因此臨床試驗計劃中亦包括兩項獨立的長期研究，集中評估「利拉利汀」對治療輕度、中度及重度腎功能受損的二型糖尿病病人的安全性及療效<ref name="#1">Barnett AJH, Harper R, Toorawa R, et al. Linagliptin monotherapy improves glycaemic control in type 2 diabetes patients for who metformin therapy is inappropriate. Poster No 823-P, 46th European Association for the Study of Diabetes Annual Meeting, 20-14 September 2010, Stockholm, Sweden. </ref> <ref name="#2">Lewin AJ, Arvay L, Liu D, et al. Safety and efficacy of linagliptin as add-on therapy to a sulphonylurea in inadequately controlled type 2 diabetes. Poster No 821-P, 46th European Association for the Study of Diabetes Annual Meeting, 20-14 September 2010, Stockholm, Sweden.</ref><ref name="#3">Owens DR, Swallow R, Kugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28(11):1352-1361. </ref><ref name="#4">Taskinen M-R, et al. Efficacy and safety of linagliptin in Type 2 diabetes inadequately controlled on metformin monotherapy. Poster No 579-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA. </ref><ref name="#5">Del Prato S, Barnett AH, Huisman H, et al. Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial. Diabetes Obes Metab 2011;13(3):258-267.</ref>  <ref name="#6">Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab 2011;13(7):653-661. </ref><ref name="#7">Kawamori R, Inagaki N, Araki E, et al. Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study. Diabetes Obes Metab 2011;Dec 6 [Epub ahead of print]. </ref><ref name="#8">Kawamori R. et al. Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. Poster number 696-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA</ref><ref name="#9">Gallwitz B, Uhlig-Laske B, Bhattacharaya S, et al. Linagliptin has similar efficacy to glimepiride but improved cardiovascular safety over 2 years in patients with type 2 diabetes inadequately controlled on metformin 71th Scientific Sessions of the American Diabetes Association, San Diego, California. 2011; Poster 39-LB.</ref>。<br />

== 療效 ==
整體研究結果顯示<ref name="#1"/> <ref name="#2"/><ref name="#3"/><ref name="#4"/><ref name="#5"/>  <ref name="#6"/><ref name="#7"/><ref name="#8"/>，無論單獨治療或合併其他抗糖尿病藥物如甲福明、磺胺脲類或格列酮類，「利拉利汀」(linagliptin)的控糖療效均十分顯著、持久而且具臨床意義。八項隨機對照研究共納入5,239名二型糖尿病病人，評估「利拉利汀」的療效和安全性。共有3,319名二型糖尿病病人接受「利拉利汀」治療，當中929名年齡65歲或以上；1,238名患有輕度腎功能受損；143名患有中度腎功能受損。結果證實，每天一次「利拉利汀」能顯著改善血糖控制，對病人體重並沒有造成具臨床意義的影響。所有子群組（性別、年齡、腎功能受損程度、體重指數）的糖化血紅素下降幅度相若。

部分研究更發現 ，「利拉利汀」能大幅改善beta細胞的功能（beta細胞負責製造及分泌胰島素）<ref name="#3"/><ref name="#4"/><ref name="#5"/>  <ref name="#6"/><ref name="#10">Kawamori R. et al. Linagliptin monotherapy improves glycemic control in Japanese patients with T2DM over 12 weeks. Poster number 696-P from the 70th American Diabetes Association Scientific Sessions, 25-29 June 2010, Orlando, Florida, USA. </ref>。

另外一項為期逾兩年的長期研究<ref name="#9"/>，比較「利拉利汀」或格列美脲加入甲福明治療後的效果12。結果顯示，「利拉利汀」能有效降糖，療效不但與格列美脲相若，而且不會引致體重上升，出現血糖過低的風險較格列美脲低，發生心血
管事件的情況也較少。目前的臨床研究証實「利拉利汀」有以下的特點：
* 持久穩定血糖至理想目標，具有臨床意義
* 安全性及耐受性良好，血糖過低的風險相當低
* 不會引致體重上升
* 無須調節藥物劑量。即使服用者同時患有其他疾病或服用其他藥物，甚至有腎功能受損，也無須調校「利拉利汀」的用藥劑量（「利拉利汀」並非主要依靠腎臟排出體外）。


== 安全性與耐受性 ==   
「利拉利汀」的整體副作用發生率與安慰劑相若，耐受性佳<ref name="#3"/><ref name="#4"/><ref name="#5"/>  <ref name="#6"/><ref name="#10"/>。即使單獨用藥或合併其他抗糖尿病藥物如甲福明、磺胺脲類或格列酮類，病人出現血糖過低的風險並無顯著增加。當與其他常用的抗糖尿病藥物合併治療，「利拉利汀」亦無產生明顯的藥物相互作用，意味着不論病人是否患有其他疾病或同時服用其他常見的藥物，都適合接受「利拉利汀」治療<ref>Scheen AJ. Dipeptidylpeptidase-4 inhibitors (Gliptins). Clin Pharmacokinet 2010;49(9):573-588.</ref><ref> Graefe-Mody U, Friedrich C, Port A, et al. Linagliptin, a novel DPP-4 inhibitor: no need for dose adjustment in patients with renal impairment. Poster No. 822-P, 46th European Association for the Study of Diabetes Annual Meeting, 20-24 September 2010, Stockholm, Sweden. </ref>。與磺胺脲類、 格列酮類或胰島素治療不同，「利拉利汀」並不會引致體重上升，亦不會產生傳統抗糖尿病藥常見的副作用<ref>Pratley R. Inhibition of DPP-4: a new therapeutic approach for the treatment of Type 2 diabetes. Curr Med Res Opin 2007;23(4):919-931.</ref>。與許多傳統二型糖尿病治療相反，開始「利拉利汀」治療時，病人無需經歷一段劑量調校期（即逐步增加劑量）以找出適當的治療劑量。<br />

== 劑量 ==   
「利拉利汀」的一般劑量是5毫克藥片。

== 不宜服用的人士 ==
* 對「利拉利汀」有效成分過敏
* 患有一型糖尿病
* 有糖尿病酮症酸中毒症
* 懷孕、正在授乳或準備授乳

== 副作用 ==
研究証實少數服用者會出現血糖過低的情況，而極少數服用者會出現過敏的情況。

==参考文献==
{{reflist|2}}

[[Category:炔烃|Category:炔烃]]
[[Category:哌啶|Category:哌啶]]
[[Category:喹唑啉|Category:喹唑啉]]
[[Category:黄嘌呤类|Category:黄嘌呤类]]